Case 2: Systemic Treatment Options
Experts in the management of thyroid cancer share their treatment recommendations for a 60-year-old man with RET+ metastatic medullary thyroid cancer.
Case 2: RET Mutations and Disease Management
The panel of experts discuss the importance of molecular testing and RET mutations in thyroid cancer disease management.
Case 2: RET+ MTC Disease Management
Dr Wirth reviews disease management considerations a 60-year-old man with RET+ metastatic medullary thyroid cancer.
TC Patient Considerations: Thyroidectomy
Lori Wirth, MD, and Andrew Gianoukakis, MD, discuss patient and clinical characteristics necessitating thyroidectomy in patients with thyroid cancer.
Case 2: RET+ Metastatic Medullary Thyroid Cancer
Lori Wirth, MD, presents the case of a 60-year-old man with RET+ metastatic medullary thyroid cancer.
Clinical Trials of BTKi in B-Cell Lymphomas
Drs Shadman and Cohen discuss clinical trial data utilizing acalabrutinib in B-cell lymphomas.
Comparing Ibrutinib, Acalabrutinib, and Zanubrutinib BTKi
Two experts compare experiences and data concerning use of ibrutinib, acalabrutinib, and zanubrutinib in B-cell lymphomas.
Lenvatinib: Dose Considerations
Marcia Brose, MD, discusses the efficacy and safety data of a phase 2 trial examining lenvatinib dose reductions in patients with RAI-DTC.
SELECT Trial: Post-Hoc Analysis
Andrew Gianoukakis, MD, and Lori Wirth, MD, examine post-hoc analysis data from the phase 3 SELECT trial.
Ibrutinib Clinical Trials for B-Cell Lymphomas
Drs Shadman and Cohen provide an overview of clinical trials utilizing the BTK inhibitor, ibrutinib, for B-cell lymphomas.
Available BTKi and Their Mechanisms of Action
Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, introduce available BTK inhibitors used as targeted therapy in B-cell malignancies.
CD19-Targeted mAbs in RR DLBCL Using Loncastuximab Tesirine
The doctors switch their monoclonal antibody conversation’s focus to longcastuximab tesirine for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
CD19-Targeted mAbs in R/R DLBCL Using Tafasitamab Continued
The discussion of tafasitamab as a monoclonal antibody therapy option for relapsed/refractory diffuse large B-cell lymphoma continues.
DTC Key Efficacy and Safety Data
Dr Andrew Gianoukakis reviews the study design and key efficacy data of the phase 3 DECISION and SELECT trials.
Thyroid Cancer Treatment Guidelines
Andrew Gianoukakis, MD, reviews the NCCN guidelines for the treatment of patients with thyroid cancer.
RR-DTC Systemic Therapy Considerations
Dr Andrew Gianoukakis, explores considerations surrounding systemic therapy in patients with RAI-refractory differentiated thyroid cancer.
RR-DTC: Molecular Testing Considerations
Marcia Brose, MD and Lori Wirth, MD, discuss molecular testing considerations in patients with radioiodine-refractory DTC.
RAI Treatment: Impact of Mutation Status
Experts in the management of thyroid cancer discuss radioactive iodine therapy and the clinical implications of mutational status in RAI- refractory DTC.
RR-DTC: Definition and Clinical Presentation
The panel of experts share their insights into the definition and clinical presentation of radioiodine-refractory DTC.
Case 1: Treatment Considerations for Refractory DTC
Andrew Gianoukakis, MD, reviews the treatment and management options for a 71-year-old woman with RAI- refractory differentiated thyroid cancer.
Case 1: Considerations of RAI Use
Experts in thyroid cancer discuss treatment considerations surrounding the use of radioiodine therapy in patients with thyroid cancer.
Case 1: RAI-Refractory DTC
Andrew Gianoukakis, MD, reviews the case of a 71-year-old woman with RAI-refractory differentiated thyroid cancer and the panel discuss relevant clinical trial data.
Potential Case Outcomes for 65-Year-Old Man With mCRC
Tanios Bekaii-Saab, MD, FACP, concludes with a discussion of potential outcomes for a 65-year-old patient with stage 4 metastatic colorectal cancer.
Subsequent Lines of Therapy and Non-Chemotherapy Options for mCRC
Dr Bekaii-Saab reviews options for subsequent lines of therapy for metastatic colorectal cancer, including non-chemotherapy options.
Capecitabine/Bevacizumab and Signs of Progression/Recurrence for mCRC
An expert elaborates on the importance of the capecitabine + bevacizumab combination therapy for metastatic colorectal cancer, as well as what signs of progression or recurrence to look for in patients.
First-Line Therapy Options for mCRC
Dr Bekaii-Saab discusses therapy options for first-line treatment of metastatic colorectal cancer.
Overview: A 65-Year-Old Man with Metastatic Colorectal Cancer
Tanios Bekaii-Saab, MD, FACP, provides an overview of a case involving a 65-year-old man diagnosed with stage 4 metastatic colorectal cancer.
CD19-Targeted mAbs in R/R DLBCL Using Tafasitamab
Dr Mazyar Shadman and Dr Brian T. Hill focus on CD19 being targeted in monoclonal antibody therapy options for relapsed/refractory diffuse large B-cell lymphoma, specifically tafasitamab.
CD19 As a Targeted Agent in CAR T Cell Therapy for R/R DLBCL
Drs Shadman and Hill discuss using CD19 as a targeted therapy option in CAR T cell therapy for relapsed/refractory diffuse large B-cell lymphoma.
Treatment Methods: Transplant Eligibility in R/R DLBCL and CAR T Cell Therapy
The experts delve further into treatment methods for relapsed/refractory diffuse large B-cell lymphoma, particular for transplant-eligible and -ineligible patients.
